

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Didier BRANELLEC et al

Examiner:

Art. Unit:

Serial No.: **09/787,995**

I.A. Filed: September 23, 1999

Title: USE OF SPECIFIC HYBRID
PROMOTERS FOR CONTROLLING
TISSUE EXPRESSION

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Commissioner
for Patents, Washington, D.C. 20231, on

7-5-2001

Date of Deposit

Signature
Dinora Walker

LATE SUBMISSION OF DECLARATION
UNDER 35 U.S.C. 371

Commissioner for Patents
BOX PCT
Washington, D.C. 20231

Sir:

In response to the "NOTIFICATION OF MISSING REQUIREMENTS UNDER 35
U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE which was mailed
on May 9, 2001 and which indicated that the oath or declaration was missing, Applicants
submit herewith the Declaration for the present application and a copy of Form
PCT/DO/EO/917.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The
Commissioner is hereby authorized to charge any additional fees which may be required by
this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this
sheet are enclosed.

Respectfully submitted,

T. Helen Payne
T. Helen Payne, Reg. No. 36,889
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5789
Telefax (908) 231-2626

Docket No. ST 98032